SCHEMBL4864451

SCHEMBL4864451

CN1CCC(Sc2ccccc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.61
PRMT6 Q96LA8 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.49
KDM1A O60341 2/20 0.44
CHRM1 P11229 2/20 0.43
CHRM2 P08172 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
CYP2D6 P10635 1/20 0.43
DRD1 P21728 1/20 0.43
SLC6A2 P23975 1/20 0.43
ADRA1A P35348 1/20 0.43
OPRM1 P35372 1/20 0.43
DRD3 P35462 1/20 0.43
SLC6A3 Q01959 1/20 0.43
KCNH2 Q12809 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
KDM4E B2RXH2 1/20 0.42
NPY1R P25929 1/20 0.42
NPY2R P49146 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21886997 0.89 CARM1 (0.54) CARM1PRMT6SMN1; SMN2KDM1ACHRM1
SCHEMBL12049742 0.82 KMT2A (0.45) CARM1PRMT6SMN1; SMN2CYP2D6KDM4E
SCHEMBL4874579 0.81 GAA (0.44) CARM1PRMT6SMN1; SMN2KDM1AKDM4E
SCHEMBL12676793 0.81 CARM1 (0.43) CARM1PRMT6SMN1; SMN2MEN1KMT2A
SCHEMBL4612660 0.81 CARM1 (0.43) CARM1PRMT6SMN1; SMN2KDM1ACHRM1
SCHEMBL18758727 0.81 POLB (0.50) CARM1PRMT6SLC6A3HTR2AHTR2C
SCHEMBL14081453 0.81 CARM1 (0.43) CARM1PRMT6SMN1; SMN2HRH3MAOB
SCHEMBL14082390 0.81 CARM1 (0.43) CARM1PRMT6SMN1; SMN2CYP2D6DRD1
SCHEMBL102816 0.80 CARM1 (0.50) CARM1PRMT6SMN1; SMN2MAPK1MAOB
SCHEMBL12110641 0.80 CARM1 (0.50) CARM1PRMT6SMN1; SMN2MAPK1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306055-A1 PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS AND ANTIOXIDANTS NIPPON SODA CO., LTD. (JP) 2009-12-10 US disclosed
US-7408067-B2 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK + CO., INC. (US) 2008-08-05 US disclosed
EP-1467986-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2004-10-20 EP disclosed
WO-2003062224-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306055-A1 PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS AND ANTIOXIDANTS NOX1, CBR1, AOX1 CARM1 1997/4885PRMT6 2852/4885SMN1; SMN2 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.